SCHEMBL30453029

SCHEMBL30453029

CCOC(=O)CNC(=O)c1ncc(-c2ccc3nc(C)ccc3c2)c(C)c1OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39
PPARA Q07869 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PPID Q08752 2/20 0.37
HSP90AA1 P07900 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
FTO Q9C0B1 1/20 0.36
EGLN1 Q9GZT9 1/20 0.36
EGLN3 Q9H6Z9 1/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257704 1.00 PPARG (0.39) PPARGPPARDPPARAKMT2AMEN1
SCHEMBL24257792 0.91 EGLN1 (0.46) KMT2AMEN1L3MBTL1MAPTTDP1
SCHEMBL30452692 0.91 EGLN1 (0.46) KMT2AMEN1L3MBTL1MAPTTDP1
SCHEMBL29248955 0.86 PPARG (0.40) PPARGPPARDPPARAKMT2AMEN1
SCHEMBL30452976 0.85 NPC1 (0.43) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL24257684 0.85 NPC1 (0.43) KMT2AMEN1NPC1RAB9AKDM4E
SCHEMBL24257795 0.84 EGLN1 (0.41) NPC1RAB9AKDM4EAKR1C3AKR1C2
SCHEMBL30452729 0.84 EGLN1 (0.41) NPC1RAB9AKDM4EAKR1C3AKR1C2
SCHEMBL24257548 0.83 EGLN1 (0.46) KMT2AMEN1L3MBTL1KDM4EMAPT
SCHEMBL24257835 0.83 VEGFA (0.49) KMT2AMEN1L3MBTL1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 PPARG 1146/4885PPARD 1682/4885PPARA 2545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.